Seattle Genetics (SGEN) Announces Presentation of SGN-CD19A Data in NHL a ASH
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large B-cell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
